Menopause

Elinzanetant reduced VMS frequency and intensity, and improved sleep and quality of life, according to the meta-analysis to be presented at the ACOG 2025 meeting.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.

The findings suggest that women who experience early menopause (age 50 years) may constitute a sex-specific high-risk group for cognitive decline.

Pooled data from the OASIS clinical trial program showed consistent efficacy of elinzanetant across BMI and smoking history subgroups, highlighting its broad applicability.

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.